The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data

Abstract

Survival data for pancreatic cancer are usually based on actuarial calculations and actual long-term survival rates are rarely reported. Here we use population-level data from the Surveillance, Epidemiology, and End Results program for patients with microscopically confirmed pancreatic ductal adenocarcinoma diagnosed from 1975 to 2011. A total of 84,275 patients with at least 5 years of follow-up were evaluated (follow-up cutoff date: December 31, 2016). Actual 5-year survival for pancreatic cancer increased from 0.9% in 1975 to 4.2% in 2011 in patients of all stages (p < 0.001), while in surgically resected patients, it rose from 1.5% to 17.4% (p < 0.001). In non-resected patients, the actual 5-year survival remained unchanged over the same time period (0.8% vs 0.9%; p = 0.121). Multivariable analysis of surgically resected patients diagnosed in the recent time era (2004–2011) showed that age, gender, grade, tumour size, TNM-stage and chemotherapy were significant independent predictors of actual 5-year survival, while age, grade and TNM-stage were significant independent predictors in non-resected patients. However, unfavourable clinicopathological factors did not preclude long-term survival. Collectively, our findings indicate that actual 5-year survival for pancreatic cancer is still below 5% despite improvement of survival for the subset of patients undergoing surgical resection.

Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians

“…After diagnosis, the overall survival ranges between four and six months, with a five-year survival rate of <5%. However, survival is significantly higher in early stage disease (IA: 31.7%; IB: 11.8%) compared to more advanced stages (IIA: 9.0%; IIB: 8.7%; III: 1.9%; IV: 0.5%) [ 6 ]. This survival disparity, even in early stages (IA vs IB) makes early diagnosis one of the most important aspects in the treatment of pancreatic cancer.…”

Organoid technology for personalized pancreatic cancer therapy

“…Pancreatic ductal adenocarcinoma is a highly aggressive tumor type with a 5-year survival rate below 5% [ 1 ]. It currently ranks as the third leading cause of cancer-mortality, but is expected to become the second leading cause in the U.S.A. by 2030 [ 2 , 3 ].…”

A Highly Responsive Pancreatic Ductal Adenocarcinoma with Liver Metastasis: A Rare Case Report

“…Additionally, the 5-year OS would significantly reduce to a dismal 3% with distant metastasis. 2 , 3 Several studies have shown that the 5-year OS of resected PDAC patients ranges from 8.1% to 30.7%. 4–6 The significant differences of the 5-year OS between resectable PDAC and PDAC of all stages demonstrated even a poorer prognosis for the 5-year OS of unresectable PDAC patients.…”